Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in GPCR signalling are implicated in the pathogenesis and treatment of neuropsychiatric55, immunological56, gastrointestinal57,58, cardiac59, renal, hormonal, infectious60 and many other disorders53,54.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [55]
In the citing paper
“most clinically effective antipsychotics also exhibit a myriad of other actions that contribute to both therapeutic and side-effect profiles [359,360].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [360]
In the citing paper
“This often generates beneficial therapeutic activities,102 due to additive or synergistic pharmacological effects.103”
From QSAR without borders (2020) · cites this paper as [102]
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376549 · Cited by 1,137
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Self-citationBurris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Research works printed but not linked: 1
- Hemrick–Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002).
Cited by
Items 101–200 of 1,000
Pehek, E. A., Nocjar, C., Roth, B. L., Byrd, T. A., & Mabrouk, O. S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300819 · Cited by 202
Self-citationPromiscuous drugs compared to selective drugs (promiscuity can be a virtue)
Mencher, S. K., & Wang, L. G. (2005) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-5-3 · Cited by 206
Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
Roskoski Jr., R. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106037 · Cited by 198
Predicting drug-target interactions using restricted Boltzmann machines
Wang, Y., & Zeng, J. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt234 · Cited by 211
Medications development to treat alcohol dependence: a vision for the next decade
Litten, R. Z., Egli, M., Heilig, M., Cui, C., Fertig, J. B., Ryan, M. L., Falk, D. E., Moss, H., Huebner, R., & Noronha, A. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00454.x · Cited by 202
Fragments, network biology and designing multiple ligands
Morphy, R., & Rankovic, Z. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 204
Neurosteroids, stress and depression: Potential therapeutic opportunities
Zorumski, C. F., Paul, S. M., Izumi, Y., Covey, D. F., & Mennerick, S. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.005 · Cited by 194
DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo
Thompson, K. J., Khajehali, E., Bradley, S. J., Navarrete, J. S., Huang, X. P., Slocum, S., Jin, J., Liu, J., Xiong, Y., Olsen, R. H. J., et al. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00012 · Cited by 193
Self-citationMaking Sense of Pharmacology: Inverse Agonism and Functional Selectivity
Berg, K. A., & Clarke, W. P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy071 · Cited by 178
Docking and chemoinformatic screens for new ligands and targets
Kolb, P., Ferreira, R. S., Irwin, J. J., & Shoichet, B. K. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.08.003 · Cited by 193
The pipeline and future of drug development in schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002062 · Cited by 184
Self-citationHopkins, A. L. (2009) · Nature · doi:10.1038/462167a · Cited by 176
Psychedelics and schizophrenia
González-Maeso, J., & Sealfon, S. C. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.005 · Cited by 166
Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data
Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., & Urban, L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700036 · Cited by 176
Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs
McCorvy, J. D., Butler, K. V., Kelly, B., Rechsteiner, K., Karpiak, J., Betz, R. M., Kormos, B. L., Shoichet, B. K., Dror, R. O., Jin, J., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2527 · Cited by 170
Self-citationA network medicine approach to human disease
Zanzoni, A., Soler-López, M., & Aloy, P. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.001 · Cited by 171
Bhatnagar, A., Sheffler, D. J., Kroeze, W. K., Compton-Toth, B., & Roth, B. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404673200 · Cited by 171
Self-citationBallante, F., Kooistra, A. J., Kampen, S., de Graaf, C., & Carlsson, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000246 · Cited by 158
Atypical Antipsychotic-Induced Weight Gain: Insights into Mechanisms of Action
Roerig, J. L., Steffen, K. J., & Mitchell, J. E. (2011) · CNS Drugs · doi:10.2165/11596300-000000000-00000 · Cited by 166
Newman‐Tancredi, A., & Kleven, M. S. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2247-y · Cited by 174
Chen, X., Choo, H., Huang, X.-P., Yang, X., Stone, O., Roth, B. L., & Jin, J. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500325v · Cited by 157
Self-citationSeyedabadi, M., Ghahremani, M. H., & Albert, P. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.006 · Cited by 162
Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology
Davies, M. A., Sheffler, D. J., & Roth, B. L. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00030.x · Cited by 156
Self-citationPhysicochemical drug properties associated with in vivo toxicological outcomes: a review
Price, D. A., Blagg, J., Jones, L., Greene, N., & Wager, T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903042318 · Cited by 147
The 'atypicality' of antipsychotics: a concept re-examined and re-defined
Gründer, G., Hippius, H., & Carlsson, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2806 · Cited by 170
Peters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 150
Analysis of multiple compound–protein interactions reveals novel bioactive molecules
Yabuuchi, H., Niijima, S., Takematsu, H., Ida, T., Hirokawa, T., Hara, T., Ogawa, T., Minowa, Y., Tsujimoto, G., & Okuno, Y. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.5 · Cited by 156
Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds
Bruni, G. N., Rennekamp, A. J., Velenich, A., McCarroll, M. N., Gendelev, L., Fertsch, E., Taylor, J. C., Lakhani, P., Lensen, D., Evron, T., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2097 · Cited by 164
Self-citationScheiber, J., Chen, B., Milik, M., Sukuru, S. C. K., Bender, A., Mikhailov, D., Whitebread, S., Hamon, J., Azzaoui, K., Urban, L., et al. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800344p · Cited by 152
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways
Dey, A., Tergaonkar, V., & Lane, D. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2759 · Cited by 169
Ehsanian, R., Waes, C. V., & Feller, S. M. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-13 · Cited by 151
Silver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53
Satapathy, S. R., Mohapatra, P., Preet, R., Das, D., Sarkar, B., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2013) · Nanomedicine · doi:10.2217/nnm.12.176 · Cited by 151
Translational research in medication development for nicotine dependence
Lerman, C. E., LeSage, M. G., Perkins, K. A., O’Malley, S. S., Siegel, S. J., Benowitz, N. L., & Corrigall, W. A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2361 · Cited by 159
Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors
Guerrant, W., Patil, V., Canzoneri, J. C., & Oyelere, A. K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm200799p · Cited by 143
Coccurello, R., & Moles, A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.008 · Cited by 163
Torres, U. S., Portela-Oliveira, E., Borgwardt, S., & Busatto, G. F. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-342 · Cited by 152
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146
Deng, C., Weston–Green, K., & Huang, X. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.009 · Cited by 166
Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases
Page, C. P., & Spina, D. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_17 · Cited by 156
Kell, D. B., Dobson, P. D., Bilsland, E., & Oliver, S. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.008 · Cited by 154
Contributions of Molecular Properties to Drug Promiscuity
Tarcsay, Á., & Keserű, G. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301514n · Cited by 153
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
Roskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106774 · Cited by 156
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs
Dong, S., Rogan, S. C., & Roth, B. L. (2010) · Nature Protocols · doi:10.1038/nprot.2009.239 · Cited by 156
Self-citationSelective PDE inhibitors as novel treatments for respiratory diseases
Page, C. P., & Spina, D. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.016 · Cited by 149
PubChem as a Source of Polypharmacology
Chen, B., Wild, D., & Guha, R. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9001876 · Cited by 140
PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors
Abbas, A. I., Yadav, P. N., Yao, W.-D., Arbuckle, M. I., Grant, S. G. N., Caron, M. G., & Roth, B. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1090-09.2009 · Cited by 136
Self-citationA Gαs DREADD Mouse for Selective Modulation of cAMP Production in Striatopallidal Neurons
Farrell, M. S., Pei, Y., Wan, Y., Yadav, P. N., Daigle, T. L., Urban, D. J., Lee, H.-M., Sciaky, N., Simmons, A., Nonneman, R. J., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.251 · Cited by 150
Self-citationTarget Identification for CNS Diseases by Transcriptional Profiling
Altar, C. A., Vawter, M. P., & Ginsberg, S. D. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.172 · Cited by 142
Wong, E. H. F., Yocca, F., Smith, M. A., & Lee, C.-M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000866 · Cited by 134
Genetics of Antipsychotic Treatment Emergent Weight Gain in Schizophrenia
Müller, D. J., & Kennedy, J. L. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.863 · Cited by 156
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.022 · Cited by 143
Maeda, K., Lerdrup, L., Sugino, H., Akazawa, H., Amada, N., McQuade, R. D., Stensbøl, T. B., Bundgaard, C., Arnt, J., & Kikuchi, T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213819 · Cited by 144
The kinase polypharmacology landscape of clinical PARP inhibitors
Antolin, A. A., Ameratunga, M., Banerji, U., Clarke, P. A., Workman, P., & Al-Lazikani, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-59074-4 · Cited by 121
O’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.162 · Cited by 144
Chemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafish
Kokel, D., & Peterson, R. T. (2008) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/eln040 · Cited by 143
Newman‐Tancredi, A., Assié, M., Leduc, N., Ormière, A.-M., Danty, N., & Cosi, C. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704005000 · Cited by 132
Schlessinger, A., Geier, E., Fan, H., Irwin, J. J., Shoichet, B. K., Giacomini, K. M., & Sali, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106030108 · Cited by 128
Hunter, A. M., Minzenberg, M. J., Cook, I. A., Krantz, D. E., Levitt, J. G., Rotstein, N. M., Chawla, S. A., & Leuchter, A. F. (2019) · Brain and Behavior · doi:10.1002/brb3.1275 · Cited by 120
Davies, M. A., Compton-Toth, B. A., Hufeisen, S. J., Meltzer, H. Y., & Roth, B. L. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2017-1 · Cited by 128
Self-citationRasmussen, H., Erritzoe, D., Andersen, R., Ebdrup, B. H., Aggernaes, B., Oranje, B., Kalbitzer, J., Madsen, J., Pinborg, L. H., Baaré, W., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.176 · Cited by 123
Kell, D. B. (2013) · The FEBS Journal · doi:10.1111/febs.12268 · Cited by 121
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
ROTHMAN, R. B., & BAUMANN, M. H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.064 · Cited by 123
Haloperidol bound D2 dopamine receptor structure inspired the discovery of subtype selective ligands
Fan, L., Tan, L., Chen, Z., Qi, J., Nie, F., Luo, Z., Cheng, J., & Wang, S. (2020) · Nature Communications · doi:10.1038/s41467-020-14884-y · Cited by 126
Lavoie, J., Illiano, P., Sotnikova, T. D., Gainetdinov, R. R., Beaulieu, J., & Hébert, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.024 · Cited by 128
Slot, L. A. B., Kleven, M. S., & Newman‐Tancredi, A. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.05.013 · Cited by 123
Paradoxical Striatal Cellular Signaling Responses to Psychostimulants in Hyperactive Mice
Beaulieu, J.-M., Sotnikova, T. D., Gainetdinov, R. R., & Caron, M. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606062200 · Cited by 116
Speech deficits in serious mental illness: A cognitive resource issue?
Cohen, A. S., McGovern, J. E., Dinzeo, T. J., & Covington, M. A. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.032 · Cited by 114
5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats
Hatcher, P. D., Brown, V. J., Tait, D. S., Bate, S. T., Overend, P., Hagan, J. J., & Jones, D. N. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2261-z · Cited by 117
The role of fragment-based and computational methods in polypharmacology
Bottegoni, G., Favia, A. D., Recanatini, M., & Cavalli, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.002 · Cited by 128
Drug Repositioning for Effective Prostate Cancer Treatment
Turanlı, B., Grøtli, M., Borén, J., Nielsen, J., Uhlén, M., Arğa, K. Y., & Mardinoğlu, A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00500 · Cited by 125
Mizuno, Y., McCutcheon, R. A., Brugger, S. P., & Howes, O. D. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0577-3 · Cited by 125
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs
Meltzer, H. Y., & Roth, B. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70678 · Cited by 109
Self-citationIkeda, M., Yamanouchi, Y., Kinoshita, Y., Kitajima, T., Yoshimura, R., Hashimoto, S., O‘Donovan, M. C., Nakamura, J., Ozaki, N., & Iwata, N. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1437 · Cited by 110
Ligands of Adrenergic Receptors: A Structural Point of View
Wu, Y., Zeng, L., & Zhao, S. (2021) · Biomolecules · doi:10.3390/biom11070936 · Cited by 121
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Roskoski, R. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106362 · Cited by 113
Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs
Boyd, K. N., & Mailman, R. B. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25761-2_3 · Cited by 107
(2024) · doi:10.1038/s42256-024-00847-1 · Cited by 108
Fernø, J., Vik‐Mo, A. O., Jassim, G., Håvik, B., Berge, K., Skrede, S., Gudbrandsen, O. A., Waage, J. E. R., Lunder, N., Mørk, S. J., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1370-x · Cited by 114
Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
Scarr, E., & Dean, B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05711.x · Cited by 104
Bardin, L., Kleven, M. S., Barret-Grévoz, C., Depoortère, R., & Newman‐Tancredi, A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300940 · Cited by 107
A pharmacological organization of G protein–coupled receptors
Lin, H., Sassano, M. F., Roth, B. L., & Shoichet, B. K. (2013) · Nature Methods · doi:10.1038/nmeth.2324 · Cited by 103
Self-citationMulti-Target Approach for Drug Discovery against Schizophrenia
Kondej, M., Stępnicki, P., & Kaczor, A. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103105 · Cited by 110
Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Zhang, W., Bai, Y., Wang, Y., & Xiao, W. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160224142812 · Cited by 112
A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.008 · Cited by 104
Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update
Roskoski, R. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107723 · Cited by 109
Network-Based Approaches in Drug Discovery and Early Development
Harrold, J. M., Ramanathan, M., & Mager, D. E. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.176 · Cited by 96
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development
Kricker, J. A., Page, C. P., Gardarsson, F. R., Baldursson, Ó., Guðjónsson, Þ., & Parnham, M. J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000300 · Cited by 109
Pharmacosynthetics: Reimagining the pharmacogenetic approach
Farrell, M. S., & Roth, B. L. (2013) · Brain Research · doi:10.1016/j.brainres.2012.09.043 · Cited by 103
Self-citationŠebestík, J., Niederhafner, P., & Ježek, J. (2010) · Amino Acids · doi:10.1007/s00726-010-0707-z · Cited by 106
Janga, S. C., & Tzakos, A. G. (2009) · Molecular BioSystems · doi:10.1039/b908147j · Cited by 110
Back to the Future with Phenotypic Screening
Prior, M., Chiruta, C., Currais, A. J. M., Goldberg, J., Ramsey, J., Dargusch, R., Maher, P. A., & Schubert, D. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500051h · Cited by 112
Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery
Ravikumar, B., & Aittokallio, T. A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1413089 · Cited by 103
Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities
Coulson, L. B., Wyllie, S., Chibale, K., & Gilbert, I. H. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00724 · Cited by 102
Privileged scaffolds in lead generation
Zhao, H., & Dietrich, J. D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041496 · Cited by 110
Lavoie, J., Maziade, M., & Hébert, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.020 · Cited by 111
Harvey, P. D., Ogasa, M., Cucchiaro, J., Loebel, A., & Keefe, R. S. E. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.004 · Cited by 95
Metz, J. T., & Hajduk, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.166 · Cited by 108
Challenges in the Search for Drugs to Treat Central Nervous System Disorders
Enna, S. J., & Williams, M. C. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143420 · Cited by 107
Recent Advances in Plant Biotechnology
Kirakosyan, A., & Kaufman, P. B. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0194-1 · Cited by 110
Metadata
- Authors
- Roth, B. L., Sheffler, D. J., & Kroeze, W. K.
- Affiliations
- Case Western Reserve University (US)
- Corresponding author
- Roth, Bryan L.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 353-359
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2122995608
- Cited by
- 1,155
- References
- 63
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 37 · 2023: 39 · 2022: 47 · 2021: 49 · 2020: 49 · 2019: 63 · 2018: 46 · 2017: 42 · 2016: 61 · 2015: 65 · 2014: 58 · 2013: 73 · 2012: 83
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- magic bullet, polygenic disease, mood disorders, schizophrenia, depression, bipolar disorder, central nervous system disorders, drug target selectivity, polypharmacology, antipsychotic drug development
- MeSH terms
- Humans, Schizophrenia, Antipsychotic Agents, Drugs, Investigational, Comorbidity, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.